ClinicalTrials.gg
RecruitingNCT06013423Updated Oct 26, 2026

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

A Phase 2 interventional study of Biospecimen Collection and Bone Marrow Aspirate in Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 6 Months to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Oct 26, 2026Eligibility revisedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
6 Months to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute — 6 open to participants now, 8 under way, none of them phase 3. Cyclophosphamide · Leukemia, Biphenotypic, Acute.

Planned enrollment
11th of 21
54 · median 54
Started
2024
the only one that year
Phase 2
16 of 23
6 open now
Registered
22nd of 23
by date
Lead sponsor
6 of 23
Fred Hutchinson Cancer Center

Among the 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute, this one is the 11th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2024, is one of 16 in phase 2, and was the 22nd registered.

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

Browse Leukemia, Biphenotypic, Acute studies →

Open to participants now

6 of the 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Leukemia, Biphenotypic, Acute studies recruiting now, 21 (45%) set no upper age limit and 21 (45%) stop at 75 or younger; 29 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cyclophosphamide in Leukemia, Biphenotypic, Acute, or all of them as a file.
02

Study summary

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.

Read the detailed description

OUTLINE: Patients are assigned to 1 of 2 arms.

ARM I: Patients aged 6 months through 30 years old receive myeloablative conditioning comprising fludarabine intravenously (IV) over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI twice daily (BID) on days -4 to -1. Patients then undergo UCBT on day 0. Patients undergo blood sample collection throughout the study. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and diagnostic imaging during screening and as clinically indicated on study. Patients also undergo blood sample collection throughout the study and bone marrow aspirate during screening and on study.

ARM II: Patients aged 6 months through 65 years old receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI once daily (QD) on days -2 and -1. Patients then undergo UCBT on day 0. Patients undergo ECHO or MUGA and diagnostic imaging during screening and as clinically indicated on study. Patients also undergo blood sample collection throughout the study and bone marrow aspirate during screening and on study.

All patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine orally (PO) (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 14 and then PO (if tolerated) three times daily (TID) on days 15-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD.

After completion of study treatment, patients are followed up at day 180, 1 year, and 2 years.

03

Conditions studied

  • Acute Leukemia of Ambiguous Lineage
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Hematopoietic and Lymphatic System Neoplasm
  • Mixed Phenotype Acute Leukemia
  • Myelodysplastic Syndrome
  • Myeloproliferative Neoplasm
  • Non-Hodgkin Lymphoma
  • Chronic Myeloid Leukemia, BCR-ABL1 Positive
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
6 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 6 months to =\< 65 years at time of consent.
  • Acute myelogenous leukemia (AML):

    • Complete first remission (CR1), complete second remission (CR2) or greater (CR2+), must have \< 5% marrow blasts at the time of transplant.
    • Patients in morphologic remission with persistent cytogenetic, flow cytometric, or molecular aberrations are eligible.
  • Acute lymphoblastic leukemia (ALL):

    • Complete first remission (CR1) at high risk for relapse such as any of the following:

      • Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality.
      • Failure to achieve MRD- complete remission after induction therapy.
      • Persistence or recurrence of minimal residual disease on therapy.
      • Any patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician.
      • Other high-risk features not defined above.
    • Complete second remission (CR2) or greater (CR2+).

      • Note: ALL with less than 5% blasts at time of transplant but persistent cytogenetic, flow cytometric or molecular aberrations are eligible.
  • Other acute leukemias: Acute leukemias of ambiguous lineage or mixed phenotype with less than 5% blasts. Leukemias in morphologic remission with persistent cytogenetic, flow cytometric or molecular aberrations are eligible.
  • Chronic Myeloid Leukemia (CML): Excluding blast crisis. To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapy.
  • Myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) other than myelofibrosis:

    • MDS/MPD overlap syndromes without myelofibrosis.
    • MDS/ MPD patients must have less than 10% bone marrow myeloblasts and (ANC) > 0.2 (growth factor supported if necessary) at transplant work-up.
  • Non-Hodgkin lymphoma (NHL) at high-risk of relapse or progression if not in remission:

    • Eligible patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histology) in CR by PET/CT imaging.
    • Eligible patients with indolent B-cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with PR or CR by PET/CT imaging.
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in morphologic remission.
  • Only for adult patients, to prevent graft rejection, patients who received only non-lymphodepleting agents for their (hypomethylating agents, venetoclax, hydroxyurea, TKIs etc.), or patients who received lymphodepleting chemotherapy > 3 months prior to scheduled admission, may receive fludarabine 25 mg/m\^2 daily x 3 days for lymphodepletion 14-42 days (aiming for 2-4 weeks) at the discretion of the principal investigator (PI).
  • For patients > 16 years old, score ≥ 70%. For patients =\< 16 years old, Lansky score ≥ 50%.
  • Calculated > 70 ml/min.
  • \< 1.5 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis).
  • (ALT) \< 3 x (ULN).
  • For patients > 18 years old, pulmonary function (spirometry and corrected diffusing capacity for carbon monoxide [DLCO]) > 60% predicted. For patients =\< 18 years old, or any patient unable to perform pulmonary function tests, O2 saturation > 92% on room air.
  • > 50%.
  • Albumin > 3.0 g/dL.
  • For patients > 18 years old, Hematopoietic Cell Transplantation Comorbidity index (HCT-CI) =\< 5.
  • UCB units will be selected according to current umbilical cord blood graft selection algorithm. One or two UCB units may be used to achieve the required cell dose.
  • The UCB graft is matched at 4-6 HLA-A, B, DRB1 antigens with the recipient. This may include 0-2 antigen mismatches at the A or B or DRB1 loci. Unit selection based on cryopreserved nucleated cell dose and HLA-A, B, DRB1 using intermediate resolution A, B antigen and DRB1 allele typing.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of myelofibrosis or other with moderate-severe bone marrow fibrosis.
  • Patients persistent with central nervous system (CNS) involvement in cerebrospinal fluid (CSF) or CNS imaging at time of screening0
  • Prior / blockade in the last 12 months.
  • Two prior stem cell transplants of any kind.
  • One prior stem cell transplant within the preceding 12 months.
  • Prior allogeneic transplantation.
  • Prior involved field radiation therapy that would preclude safe delivery of 400cGy total body irradiation (TBI) in the opinion of radiation oncology.
  • Active and uncontrolled infection at time of transplantation.
  • infection.
  • Inadequate performance status/ organ function.
  • Pregnancy or breast feeding.
  • Patient or guardian unable to give or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Arm I (myeloablative UCBT)

    See detailed description.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspirate · Drug: Cyclophosphamide · Drug: Cyclosporine · Procedure: Diagnostic Imaging Testing · Procedure: Echocardiography Test · Drug: Fludarabine Phosphate · Procedure: Multigated Acquisition Scan · Drug: Mycophenolate Mofetil · Other: Survey Administration · Radiation: Total-Body Irradiation · Procedure: Umbilical Cord Blood Transplantation

  • Experimental
    Arm II (myeloablative UCBT)

    See detailed description.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspirate · Drug: Cyclophosphamide · Drug: Cyclosporine · Procedure: Diagnostic Imaging Testing · Procedure: Echocardiography Test · Drug: Fludarabine Phosphate · Procedure: Multigated Acquisition Scan · Drug: Mycophenolate Mofetil · Other: Survey Administration · Drug: Thiotepa · Radiation: Total-Body Irradiation · Procedure: Umbilical Cord Blood Transplantation

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspirate

    Undergo bone marrow aspirate

    Also known as: BONE MARROW, LIQUID, Human Bone Marrow Aspirate

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, Frindovyx

  • Given IV or PO

    Also known as: 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Cyclosporine Modified, Gengraf, Neoral, OL 27-400, Sandimmune, SangCya

  • ProcedureDiagnostic Imaging Testing

    Undergo diagnostic imaging

    Also known as: Diagnostic Imaging, Medical Imaging

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • Given IV

    Also known as: 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: CellCept, MMF

  • OtherSurvey Administration

    Ancillary studies

  • Given IV

    Also known as: 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, SH105

  • RadiationTotal-Body Irradiation

    Undergo high-dose or middle-intensity TBI

    Also known as: SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation

  • ProcedureUmbilical Cord Blood Transplantation

    Undergo UCBT

    Also known as: Cord Blood, Cord Blood Transplantation, UCB transplantation, UMBILICAL CORD BLOOD TRANSPLANT

06

What researchers measure

Primary outcomes

  1. Overall survival

    Will be assessed after optimized cord blood transplant (CBT) in adults and children with hematologic malignancies. Will be calculated using the Kaplan-Meier method.

    Time frame: At 1 year

Secondary outcomes

  1. Cumulative incidence of neutrophil and platelet engraftment

    Will be calculated within the competing risks framework considering death without neutrophil or platelet recovery, respectively, as completing events

    Time frame: Up to 1 year

  2. Incidences of graft failure

    Will be calculated within the competing risks framework considering death without engraftment before day 21 as a competing event.

    Time frame: Up to 1 year

  3. Incidence of grade II-IV and III-IV acute graft-versus-host disease (aGVHD)

    Will be calculated within the competing risks framework considering relapse/ death without developing GVHD, death in the absence of relapse, and relapse as competing events, respectively.

    Time frame: At day 100

  4. Incidence of grade II-IV and III-IV aGVHD

    Will be calculated within the competing risks framework considering relapse/ death without developing GVHD, death in the absence of relapse, and relapse as competing events, respectively.

    Time frame: At day 180

  5. Incidence of chronic graft-versus-host disease (cGVHD)

    Will be calculated within the competing risks framework considering relapse/ death without developing GVHD, death in the absence of relapse, and relapse as competing events, respectively.

    Time frame: At 1, 2 and 3 years

  6. Organ distribution of GVHD

    Will be calculated within the competing risks framework considering death without neutrophil or platelet recovery, respectively, as completing events

    Time frame: Up to 1 year

  7. Incidence of adverse events

    Will be assessed using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).

    Time frame: Up to 1 year

  8. Time to immunosuppression cessation

    Will be assessed using CTCAE v 5.0.

    Time frame: Up to 1 year

  9. Pattern of donor chimerism

    Will be assessed using CTCAE v 5.0.

    Time frame: Up to 1 year

  10. Incidence of pre-engraftment syndrome (PES)

    Will be assessed using CTCAE v 5.0.

    Time frame: Up to 1 year

  11. Incidence of transplant related mortality (TRM)

    Time frame: At 100 days, 6 months, 1 and 2 years

  12. Incidence of relapse

    Time frame: At 1, and 2 years after CBT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Oct 2031, 87 months after the start.

Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 87 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2023
First posted
Aug 28, 2023
StartActual
Jul 23, 2024
Primary completionEst.
Oct 31, 2031
CompletionEst.
Oct 31, 2032
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedFor patients > 1816 years old, Karnofsky score ≥ 70%. For patients =< 1816 years old, Lansky score ≥ 50%.
Oct 26, 2026
Interventions
Changed Diagnostic Imaging→Diagnostic Imaging Testing; Echocardiography→Echocardiography Test
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedFor patients > 1816 years old, Karnofsky score ≥ 70%. For patients =< 1816 years old, Lansky score ≥ 50%.
    Interventions Changed Diagnostic Imaging→Diagnostic Imaging Testing; Echocardiography→Echocardiography Test
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06013423
Collaborators
National Cord Blood Network
Responsible party
Sponsor
First posted
Aug 28, 2023
Start date
Jul 23, 2024
Primary completion
Oct 31, 2031 (estimated)
Completion
Oct 31, 2032 (estimated)
Last update
Oct 26, 2026

Study contacts

Ann Dahlberg
Contact
adahlber@fredhutch.org
206-667-1959
Ann Dahlberg
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine phosphate

Start the discussion